In summary, the characterization of patient‐associated Bcl‐xL mutations reveals the importance of developing new strategies beyond canonical Bcl‐xL inhibitors to ablate both antiapoptotic and metastatic functions of Bcl‐xL in cancer. The gene discussed is BCL2L1; the disease is cancer.